Adverse drug events and toxicological mechanisms of esketamine: a study based on US Food and Drug Administration Adverse Event Reporting System and network toxicology analysis.
Naunyn Schmiedebergs Arch Pharmacol February 26, 2026 DOI: 10.1007/s00210-026-05108-z via PubMed
Summary
Esketamine, a drug used for treatment-resistant depression, is associated with a range of adverse drug events, including psychiatric, neurological, and cardiovascular effects. Analysis of reports from the US Food and Drug Administration Adverse Event Reporting System identified the most common adverse events as dissociation, sedation, and increased blood pressure. Network toxicology analysis suggested that esketamine may interact with multiple biological targets and pathways, potentially explaining its toxicological mechanisms. The findings indicate that while esketamine is effective, careful monitoring for specific adverse events is warranted.
Study at a glance
| Characteristics | Observational study with network toxicology analysis Peer reviewed |
|---|---|
| Population | Patients who experienced adverse events reported to the US FDA Adverse Event Reporting System |
| Citations | 1 |
| Key finding | Esketamine is associated with adverse events including dissociation, sedation, and increased blood pressure, and network toxicology analysis suggests multiple biological targets and pathways involved in its toxicological mechanisms. |
Abstract
Adverse drug events and toxicological mechanisms of esketamine: a study based on US Food and Drug Administration Adverse Event Reporting System and network toxicology analysis.